^
Association details:
Biomarker:GOLM1 overexpression
Cancer:Uveal Melanoma
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response

Published date:
11/18/2022
Excerpt:
SubMap analyses confirmed the indicator role of GOLM1 in predicting immunotherapy response in UVM….We also predicted the potential responders with the SubMap analysis of a melanoma cohort receiving anti-PD-1 and anti-CTLA4 therapies, demonstrating that patients in the HEXP group are more likely to be sensitive to both anti-CTLA4 and anti-PD-1/PD-L1 therapies....Taken together, GOLM1 is a novel prognostic marker, and it can be employed to predict the overall survival outcomes and treatment responses of anti-PD-1/PD-L1 and anti-CTLA4 therapies for UVM patients.
DOI:
10.3389/fgene.2022.1051168